The world watched in horror as Christian Eriksen collapsed on the pitch during Denmark’s Euro 2020 opener. But what followed was a testament to human ingenuity and the quiet heroism of British medical technology. The device that restarted his heart, a subcutaneous implantable cardioverter-defibrillator (S-ICD), was developed by a team at St. George's Hospital in London. Today, as Eriksen prepares to return to competitive football, we are forced to confront a future where such miracles become routine. But at what cost?
Let me be clear: I am not a doctor. But I have spent years tracking the convergence of biology and data, and the Eriksen story is a powerful case study. The S-ICD is a marvel: it monitors heart rhythms and delivers a shock when needed, all without touching the heart itself. It is less invasive than older models, but it still raises profound questions. Every device that keeps us alive also generates data. Who owns that data? Where does it go? And what happens when a machine decides you are dying?
We tend to celebrate these innovations without pausing to think about the Black Mirror consequences. Imagine a future where your heart implant is hacked, or where insurance companies access your cardiac data to adjust premiums. That is not science fiction. It is a plausible scenario if we do not establish digital sovereignty now. The same technology that saved Eriksen could be used to discriminate against him later.
Then there is the user experience of society. We celebrate the individual miracle but ignore the systemic failure that made it necessary. Eriksen had no known heart condition before his collapse. The device is a fix, not a cure. Are we becoming too reliant on tech to solve problems that better prevention could avoid? The NHS spends millions on these devices, but a fraction of that on screening. It is a classic Silicon Valley mindset: break something, then sell the fix.
I spoke to a biophysicist at Cambridge who argues that the S-ICD is just the beginning. Within a decade, we will have implants that not only save lives but also enhance biology. Heart patches that regenerate tissue. Brain-computer interfaces that restore memories. The line between therapy and augmentation will blur. And the companies that own these technologies will own a piece of you.
But let us not be entirely dystopian. The fact that Eriksen can walk out onto a World Cup pitch again is extraordinary. It is a triumph of human collaboration: the Danish medical team, the British engineers, the Swiss regulators. This is the good side of globalisation. The technology is open-source in spirit, even if patents restrict it. And the data from Eriksen’s device is being shared with researchers to improve outcomes for others.
So where does that leave us? We must demand transparency. Every device marketed as life-saving should come with a data rights charter. We need a digital bill of rights for implantable tech: the right to know what data is collected, the right to opt out of sharing, and the right to have that data deleted. The EU’s GDPR is a start, but it is not enough. Medical devices fall into a loophole that data privacy laws have not yet closed.
For now, let us celebrate Christian Eriksen’s return. But as we cheer, we must also watch. The technology that saved him is a miracle, but only if we control it. Otherwise, it becomes a leash. The future is here, and it is beautiful and terrifying in equal measure. The question is: are we building a world that serves us, or one that serves the algorithms?
Julian Vane is Technology & Innovation Lead. He writes about the intersection of biology, data and society.
